Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelly, I. E.
Right arrow Articles by Lean, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, I. E.
Right arrow Articles by Lean, M. E.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 22, Issue 2 288-293, Copyright © 1999 by American Diabetes Association

ARTICLES

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

IE Kelly, TS Han, K Walsh and ME Lean
Department of Human Nutrition, University of Glasgow, Glasgow Royal Infirmary, Scotland, U.K.

OBJECTIVE: To examine the effects of a thiazolidinedione (600 mg troglitazone) insulin-sensitizing treatment on total body fat measured by underwater weighing, on intra- and extra-abdominal fat mass using magnetic resonance imaging (MRI), and on anthropometric measures. RESEARCH DESIGN AND METHODS: Type 2 diabetic outpatients were studied in a double-blind randomized trial carried out at Glasgow Royal Infirmary, Scotland. RESULTS: Groups who received troglitazone (8 men, 3 women) and placebo (8 men, 2 women) were well matched for age, BMI, total body fat percentage by underwater weighing, and intra-abdominal fat (kilograms) by MRI. After 12 weeks, body weight changes in the troglitazone group (mean +0.66 kg [95% CI -0.71 to 2.04], P = 0.31) and the placebo group (mean +0.25 kg [-0.64 to 1.13], P = 0.55) were not statistically different. Changes in total body fat with troglitazone (mean +1.02% body wt [-1.13 to 3.17], P = 0.32) and placebo (mean -0.54% body wt [-1.68 to 0.59], P = 0.31) were not significantly different. There was, however, a decrease in intra-abdominal fat mass in the troglitazone-treated group (mean -0.47 kg [-0.79 to -0.13], P = 0.01), and this was significantly different (P = 0.03) from placebo treatment (mean -0.41 kg [-0.77 to -0.05]). CONCLUSIONS: Treatment with the thiazolidinedione troglitazone in human patients with type 2 diabetes decreases intra-abdominal fat mass but does not affect total body fat or weight. This potentially valuable effect points to a differential action on insulin sensitivity in different adipose tissue depots.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
M. C. Carmona, K. Louche, B. Lefebvre, A. Pilon, N. Hennuyer, V. Audinot-Bouchez, C. Fievet, G. Torpier, P. Formstecher, P. Renard, et al.
S 26948: a New Specific Peroxisome Proliferator Activated Receptor {gamma} Modulator With Potent Antidiabetes and Antiatherogenic Effects
Diabetes, November 1, 2007; 56(11): 2797 - 2808.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. M. Pou, J. M. Massaro, U. Hoffmann, R. S. Vasan, P. Maurovich-Horvat, M. G. Larson, J. F. Keaney Jr, J. B. Meigs, I. Lipinska, S. Kathiresan, et al.
Visceral and Subcutaneous Adipose Tissue Volumes Are Cross-Sectionally Related to Markers of Inflammation and Oxidative Stress: The Framingham Heart Study
Circulation, September 11, 2007; 116(11): 1234 - 1241.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. Jia, H. Wu, Y. Bao, C. Wang, J. Lu, J. Zhu, and K. Xiang
Association of Serum Retinol-Binding Protein 4 and Visceral Adiposity in Chinese Subjects with and without Type 2 Diabetes
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3224 - 3229.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. C. Granberry, J. B. Hawkins, and A. M. Franks
Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure
Am. J. Health Syst. Pharm., May 1, 2007; 64(9): 931 - 936.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
T. S Han, N. Sattar, and M. Lean
ABC of obesity. Assessment of obesity and its clinical implications.
BMJ, September 30, 2006; 333(7570): 695 - 698.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
E. S. Kang, B. S. Cha, H. J. Kim, H. J. Kim, S. H. Kim, K. Y. Hur, H. J. Lee, W. S. Shim, C. W. Ahn, and H. C. Lee
The 11482G>A Polymorphism in the Perilipin Gene Is Associated With Weight Gain With Rosiglitazone Treatment in Type 2 Diabetes.
Diabetes Care, June 1, 2006; 29(6): 1320 - 1324.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
K. Rautio, J.S. Tapanainen, A. Ruokonen, and L.C. Morin-Papunen
Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study
Hum. Reprod., June 1, 2006; 21(6): 1400 - 1407.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
P. Iglesias and J. J Diez
Peroxisome proliferator-activated receptor gamma agonists in renal disease.
Eur. J. Endocrinol., May 1, 2006; 154(5): 613 - 621.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Franckhauser, S. Munoz, I. Elias, T. Ferre, and F. Bosch
Adipose Overexpression of Phosphoenolpyruvate Carboxykinase Leads to High Susceptibility to Diet-Induced Insulin Resistance and Obesity
Diabetes, February 1, 2006; 55(2): 273 - 280.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
J R Porter and T G Barrett
Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and {beta} cell failure
J. Med. Genet., December 1, 2005; 42(12): 893 - 902.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. K. Wolford, K. A. Yeatts, S. K. Dhanjal, M. H. Black, A. H. Xiang, T. A. Buchanan, and R. M. Watanabe
Sequence Variation in PPARG May Underlie Differential Response to Troglitazone
Diabetes, November 1, 2005; 54(11): 3319 - 3325.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B.-S. Cha, T. P. Ciaraldi, K.-S. Park, L. Carter, S. R. Mudaliar, and R. R. Henry
Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPAR{gamma} agonists
Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E151 - E159.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E.C. Tok, A. Aktas, D. Ertunc, E.M. Erdal, and S. Dilek
Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-{gamma}2 Pro12Ala genotype
Hum. Reprod., June 1, 2005; 20(6): 1590 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Ortega-Gonzalez, S. Luna, L. Hernandez, G. Crespo, P. Aguayo, G. Arteaga-Troncoso, and A. Parra
Responses of Serum Androgen and Insulin Resistance to Metformin and Pioglitazone in Obese, Insulin-Resistant Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1360 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
A. Y.Y. Cheng and I. G. Fantus
Oral antihyperglycemic therapy for type 2 diabetes mellitus
Can. Med. Assoc. J., January 18, 2005; 172(2): 213 - 226.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. Grohmann, M. Sabin, J. Holly, J. Shield, E. Crowne, and C. Stewart
Characterization of differentiated subcutaneous and visceral adipose tissue from children: the influences of TNF-{alpha} and IGF-I
J. Lipid Res., January 1, 2005; 46(1): 93 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
T. Tchkonia, Y. D. Tchoukalova, N. Giorgadze, T. Pirtskhalava, I. Karagiannides, R. A. Forse, A. Koo, M. Stevenson, D. Chinnappan, A. Cartwright, et al.
Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots
Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E267 - E277.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S Jadhav, J Petrie, W Ferrell, S Cobbe, and N Sattar
Insulin resistance as a contributor to myocardial ischaemia independent of obstructive coronary atheroma: a role for insulin sensitisation?
Heart, December 1, 2004; 90(12): 1379 - 1383.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
M A. Soroceanu, D. Miao, X.-Y. Bai, H. Su, D. Goltzman, and A. C Karaplis
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis
J. Endocrinol., October 1, 2004; 183(1): 203 - 216.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Miyazaki, A. Mahankali, E. Wajcberg, M. Bajaj, L. J. Mandarino, and R. A. DeFronzo
Effect of Pioglitazone on Circulating Adipocytokine Levels and Insulin Sensitivity in Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4312 - 4319.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith
The Effect of Pioglitazone on Peroxisome Proliferator-Activated Receptor-{gamma} Target Genes Related to Lipid Storage In Vivo
Diabetes Care, July 1, 2004; 27(7): 1660 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Bays, L. Mandarino, and R. A. DeFronzo
Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
K. M. Ogilvie, R. Saladin, T. R. Nagy, M. S. Urcan, R. A. Heyman, and M. D. Leibowitz
Activation of the Retinoid X Receptor Suppresses Appetite in the Rat
Endocrinology, February 1, 2004; 145(2): 565 - 573.
[Abstract] [Full Text] [PDF]

Home page
 Recent Prog Horm ResHome page
J. R. Seckl, N. M. Morton, K. E. Chapman, and B. R. Walker
Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue
Recent Prog. Horm. Res., January 1, 2004; 59(1): 359 - 393.
[Abstract] [Full Text]

Home page
 Diabetes CareHome page
K. Levin, O. Hother-Nielsen, J. E. Henriksen, and H. Beck-Nielsen
Effects of Troglitazone in Young First-Degree Relatives of Patients With Type 2 Diabetes
Diabetes Care, January 1, 2004; 27(1): 148 - 154.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al.
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A consensus statement from the American Heart Association and American Diabetes Association
Diabetes Care, January 1, 2004; 27(1): 256 - 263.
[Full Text] [PDF]

Home page
 CirculationHome page
R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al.
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association
Circulation, December 9, 2003; 108(23): 2941 - 2948.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
S. Shadid and M. D. Jensen
Effects of Pioglitazone Versus Diet and Exercise on Metabolic Health and Fat Distribution in Upper Body Obesity
Diabetes Care, November 1, 2003; 26(11): 3148 - 3152.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
T. Mae, H. Kishida, T. Nishiyama, M. Tsukagawa, E. Konishi, M. Kuroda, Y. Mimaki, Y. Sashida, K. Takahashi, T. Kawada, et al.
A Licorice Ethanolic Extract with Peroxisome Proliferator-Activated Receptor-{gamma} Ligand-Binding Activity Affects Diabetes in KK-Ay Mice, Abdominal Obesity in Diet-Induced Obese C57BL Mice and Hypertension in Spontaneously Hypertensive Rats
J. Nutr., November 1, 2003; 133(11): 3369 - 3377.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. Gavrilova, M. Haluzik, K. Matsusue, J. J. Cutson, L. Johnson, K. R. Dietz, C. J. Nicol, C. Vinson, F. J. Gonzalez, and M. L. Reitman
Liver Peroxisome Proliferator-activated Receptor {gamma} Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass
J. Biol. Chem., September 5, 2003; 278(36): 34268 - 34276.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. B. Savage, G. D. Tan, C. L. Acerini, S. A. Jebb, M. Agostini, M. Gurnell, R. L. Williams, A. M. Umpleby, E. L. Thomas, J. D. Bell, et al.
Human Metabolic Syndrome Resulting From Dominant-Negative Mutations in the Nuclear Receptor Peroxisome Proliferator-Activated Receptor-{gamma}
Diabetes, April 1, 2003; 52(4): 910 - 917.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. A. Phillips, T. P. Ciaraldi, A. P.S. Kong, R. Bandukwala, V. Aroda, L. Carter, S. Baxi, S. R. Mudaliar, and R. R. Henry
Modulation of Circulating and Adipose Tissue Adiponectin Levels by Antidiabetic Therapy
Diabetes, March 1, 2003; 52(3): 667 - 674.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. A. Virtanen, K. Hallsten, R. Parkkola, T. Janatuinen, F. Lonnqvist, T. Viljanen, T. Ronnemaa, J. Knuuti, R. Huupponen, P. Lonnroth, et al.
Differential Effects of Rosiglitazone and Metformin on Adipose Tissue Distribution and Glucose Uptake in Type 2 Diabetic Subjects
Diabetes, February 1, 2003; 52(2): 283 - 290.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Laplante, H. Sell, K. L. MacNaul, D. Richard, J. P. Berger, and Y. Deshaies
PPAR-{gamma} Activation Mediates Adipose Depot-Specific Effects on Gene Expression and Lipoprotein Lipase Activity: Mechanisms for Modulation of Postprandial Lipemia and Differential Adipose Accretion
Diabetes, February 1, 2003; 52(2): 291 - 299.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
R. A Defronzo
Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance?
The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1_suppl): S24 - S40.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
S. M. Strowig, M. L. Aviles-Santa, and P. Raskin
Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Troglitazone in Type 2 Diabetes
Diabetes Care, October 1, 2002; 25(10): 1691 - 1698.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
O. Paulmyer-Lacroix, S. Boullu, C. Oliver, M.-C. Alessi, and M. Grino
Expression of the mRNA Coding for 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue from Obese Patients: An in Situ Hybridization Study
J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2701 - 2705.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, K. Cusi, L. J. Mandarino, and R. A. DeFronzo
Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2784 - 2791.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
T. Tchkonia, N. Giorgadze, T. Pirtskhalava, Y. Tchoukalova, I. Karagiannides, R. A. Forse, M. DePonte, M. Stevenson, W. Guo, J. Han, et al.
Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2002; 282(5): R1286 - R1296.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
K. Takami, N. Takeda, K. Nakashima, R. Takami, M. Hayashi, S. Ozeki, A. Yamada, Y. Kokubo, M. Sato, S.-i. Kawachi, et al.
Effects of Dietary Treatment Alone or Diet With Voglibose or Glyburide on Abdominal Adipose Tissue and Metabolic Abnormalities in Patients With Newly Diagnosed Type 2 Diabetes
Diabetes Care, April 1, 2002; 25(4): 658 - 662.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. P. Sewter, F. Blows, A. Vidal-Puig, and S. O'Rahilly
Regional Differences in the Response of Human Pre-Adipocytes to PPAR{gamma} and RXR{alpha} Agonists
Diabetes, March 1, 2002; 51(3): 718 - 723.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. B. Mayerson, R. S. Hundal, S. Dufour, V. Lebon, D. Befroy, G. W. Cline, S. Enocksson, S. E. Inzucchi, G. I. Shulman, and K. F. Petersen
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Diabetes, March 1, 2002; 51(3): 797 - 802.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. E. Inzucchi
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
JAMA, January 16, 2002; 287(3): 360 - 372.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. P. Ciaraldi, A. P.S. Kong, N. V. Chu, D. D. Kim, S. Baxi, M. Loviscach, R. Plodkowski, R. Reitz, M. Caulfield, S. Mudaliar, et al.
Regulation of Glucose Transport and Insulin Signaling by Troglitazone or Metformin in Adipose Tissue of Type 2 Diabetic Subjects
Diabetes, January 1, 2002; 51(1): 30 - 36.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
B. Staels
The clinical significance of PPAR{alpha} and {gamma} agonism
The British Journal of Diabetes & Vascular Disease, January 1, 2002; 2(1_suppl): S28 - S31.
[Abstract] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
Y. Arad, D. Newstein, F. Cadet, M. Roth, and A. D. Guerci
Association of Multiple Risk Factors and Insulin Resistance With Increased Prevalence of Asymptomatic Coronary Artery Disease by an Electron-Beam Computed Tomographic Study
Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 2051 - 2058.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. J. de Souza, M. Eckhardt, K. Gagen, M. Dong, W. Chen, D. Laurent, and B. F. Burkey
Effects of Pioglitazone on Adipose Tissue Remodeling Within the Setting of Obesity and Insulin Resistance
Diabetes, August 1, 2001; 50(8): 1863 - 1871.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Y. Miyazaki, A. Mahankali, M. Matsuda, L. Glass, S. Mahankali, E. Ferrannini, K. Cusi, L. J. Mandarino, and R. A. DeFronzo
Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone
Diabetes Care, April 1, 2001; 24(4): 710 - 719.
[Abstract] [Full Text]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
M. E. Lean
The role of central fat accumulation in type 2 diabetes
The British Journal of Diabetes & Vascular Disease, March 1, 2001; 1(2): 115 - 117.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
A. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca
Nonhypoglycemic Effects of Thiazolidinediones
Ann Intern Med, January 2, 2001; 134(1): 61 - 71.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. E. Lebovitz, J. F. Dole, R. Patwardhan, E. B. Rappaport, and M. I. Freed
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 280 - 288.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
O. P. Ganda
Lipoatrophy, Lipodystrophy, and Insulin Resistance
Ann Intern Med, August 15, 2000; 133(4): 304 - 306.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1999 by the American Diabetes Association.